Human T-cell heterogeneity as delineated with a specific human thymus lymphocyte antiserum. In vitro effects on mitogen response mixed leukocyte culture, cell-mediated lymphocytotoxicity, and lymphokine production.
Human peripheral blood lymphocytes (PBL) were evaluated by their responses to phytohemmagglutinin (PHA-P), concanavallin A (con-A), and pokeweed mitogen (PWM), both before and after treatment with an antiserum against human thymic lymphocyte antigens (HTLA) that had been made T-cell-specific by multiple absorptions with immunoglobulin EAC-positive lymphoblast cell lines (B cells). Cells treated with HTLA were examined for their ability to react in a mixed lymphocyte culture (MLC) and to form killer cells in a cell-mediated lymphocytotoxicity (CML) system. Sensitized cells were also examined for their ability to respond to purified protein derivative (PPD) by blastogenesis, migration inhibitory factor release (MIP), and lymphotoxin (LT) production, both before and after treatment with HTLA and complement. The HTLA was in itself highly stimulatory to PBL. However, with the addition of complement and subsequent cell destruction, a marked decrease in its stimulatory response was noted. PBL treated with HTLA and complement exhibited marked inhibition of responsiveness to con-A with little decrease in PHA-P -OR PWM stimulation except at very high concentration of HTLA. MLC reaction was inhibited only when responder cells were treated with HTLA + C'. Treatment of stimulator cells with HTLA + C' did not significantly alter the MLC response. The HTLA + C'-treated cells failed to form killer cells in the CML reaction and inhibited PPD-induced blasto-genesis from PPD-sensitized individuals; however, treatment of sensitized cells with HTLA + C' had little effects on the release of MIF and LT. It is suggested that subpopulations of T-cells carry surface antigens that bind with this specific antisera, and that the con-A-responsive cells, the responder cells in the MLC, and killer T-cells comprise a separate subset from cells responding to PHA-P or PWM, OR THE MIF-and LT-producing cells.
D000818:Animals; D000961:Antilymphocyte Serum; D002460:Cell Line; D003165:Complement System Proteins; D003208:Concanavalin A; D003601:Cytotoxicity Tests, Immunologic; D006650:Histocompatibility Testing; D006801:Humans; D007104:Immune Adherence Reaction; D007136:Immunoglobulins; D066298:In Vitro Techniques; D037102:Lectins; D007945:Leukemia, Lymphoid; D008213:Lymphocyte Activation; D008233:Lymphotoxin-alpha / Q000096:biosynthesis; D008263:Macrophage Migration-Inhibitory Factors / Q000378:metabolism; D008934:Mitogens; D010936:Plant Extracts; D011817:Rabbits / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology* / Q000378:metabolism; D014373:Tuberculin
D000961:Antilymphocyte Serum; D007136:Immunoglobulins; D037102:Lectins; D008233:Lymphotoxin-alpha; D008263:Macrophage Migration-Inhibitory Factors; D008934:Mitogens; D010936:Plant Extracts; D014373:Tuberculin; D003208:Concanavalin A; D003165:Complement System Proteins